Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPEN-LABEL, MULTICENTRE, RANDOMIZED CLINICAL TRIAL TO COMPARE THE PHARMACOKINETICS OF ENVARSUS TABLETS AND ADVAGRAF CAPSULES ADMINISTERED ONCE DAILY IN ADULT DE-NOVO KIDNEY TRANSPLANT PATIENTS

Next Previous
Search
Trial Profile

OPEN-LABEL, MULTICENTRE, RANDOMIZED CLINICAL TRIAL TO COMPARE THE PHARMACOKINETICS OF ENVARSUS TABLETS AND ADVAGRAF CAPSULES ADMINISTERED ONCE DAILY IN ADULT DE-NOVO KIDNEY TRANSPLANT PATIENTS

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici

Most Recent Events

  • 12 Sep 2021 Data from this study was used to predict the initial doses of the once-daily prolonged release tacrolimus Envarsus (LCPT) in adult kidney recipients by POPPK model, published in the Advances in Therapy
  • 14 Dec 2018 Results published in the Advances in Therapy
  • 03 Oct 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top